On Nov 02, major Wall Street analysts update their ratings for $Merck & Co (MRK.US)$, with price targets ranging from $120 to $125.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and maintains the target price at $123.
BofA Securities analyst Charlie CY Yang maintains with a buy rating, and maintains the target price at $120.
UBS analyst Colin Bristow maintains with a buy rating, and adjusts the target price from $142 to $125.
Leerink Partners analyst Joseph Schwartz maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Merck & Co (MRK.US)$'s main analysts recently are as follows:
Ongoing uncertainty surrounding Gardasil and the market in China as we approach 2024 has been highlighted following the company's third quarter report. The analyst has revised estimates subsequent to the third quarter earnings surpassing expectations and the company largely maintaining its outlook.
Merck's third-quarter results slightly surpassed expectations in terms of revenue and earnings. Despite this, the company's stock faced a bit of pressure following the adjustment of their revenue forecast and a reduction in EPS guidance, now anticipated to be between $7.72 and $7.77, primarily due to a charge associated with previous acquisitions. Looking ahead, while revenue projections for 2024 remain largely the same with a slight increase in EPS expectations, estimates for 2025 have been scaled back on account of anticipated lower Gardasil sales and heightened operational expenditures.
Merck's adjustment of expectations for Gardasil is seen as a positive development, although the introduction of new investments may still require a shift in narrative. The potential of Winrevair to catalyze this change remains uncertain.
Here are the latest investment ratings and price targets for $Merck & Co (MRK.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
